Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus GG
- Development stage
- Phase 4
- Lead developer
- Novonesis
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus GG (LGG) is a well-characterized probiotic bacterial strain being investigated by the Campus Bio-Medico University for its potential to prevent relapses in patients with vernal keratoconjunctivitis (VKC). VKC is a chronic, severe allergic eye disease primarily affecting children and adolescents, characterized by ocular inflammation. The therapeutic approach involves the oral administration of LGG to modulate the systemic immune system and the gut-eye axis, thereby reducing the frequency and severity of inflammatory relapses. This represents a novel management strategy for VKC, shifting focus from traditional topical treatments to systemic immunomodulation via the microbiome.
- Brand names
- CulturelleDicoflor 60Dicoflor60Dicoflor-60
- Other names
- LGGLactobacillus GGATCC 53103ATCC53103ATCC-53103
02
Targets
EGFR (Epidermal growth factor receptor)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Lactobacillus rhamnosus GG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus GG.